|
|
|
|
Getting an antibody-drug conjugate to commercial supply starts with early payload-linker strategy and synthetic route design, matched to manufacturing scale and integrated drug substance and drug product planning across the value chain.
|
|
|
|
|
Site-specific conjugation usually requires antibody engineering, which lowers yields and adds complexity. This nongenetic method combines enzymatic glycan remodeling with click chemistry to yield homogeneous, stable ADCs from any IgG isotype.
|
|
|
|
|
Scaling spray-dried dispersions takes more than larger batches. Find out how early planning and deeper process understanding can preserve performance and reduce commercialization risk as a program moves toward commercial supply.
|
|
|
|
|
Small molecule APIs are growing more complex and potent just as expedited regulatory pathways compress timelines. Learn how that pressure on synthesis, scale-up, and partner selection is reshaping how programs are planned.
|
|
|
|
|
|
|
Iwan Bertholjotti, Lonza’s Senior Director of Commercial Development for Bioconjugates, explains how the company is expanding its bioconjugates capabilities to support seamless progression from clinical development to commercial manufacturing.
|
|
|
|
|
See how integrated late-phase bioconjugate capabilities and scalable manufacturing strategies are helping address the challenges of emerging modalities as they advance toward commercial production.
|
|
|
